135,000 Shares in Annexon, Inc. (NASDAQ:ANNX) Bought by Swiss National Bank

Swiss National Bank acquired a new position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,000 shares of the company's stock, valued at approximately $693,000. Swiss National Bank owned 0.13% of Annexon as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ANNX. State Street Corp boosted its position in shares of Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company's stock worth $22,744,000 after acquiring an additional 2,068,294 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Annexon by 221.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company's stock worth $4,335,000 after purchasing an additional 504,656 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Annexon by 56.2% in the 4th quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company's stock valued at $5,282,000 after purchasing an additional 370,426 shares in the last quarter. Candriam S.C.A. increased its stake in shares of Annexon by 15.6% in the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock valued at $13,001,000 after purchasing an additional 341,431 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Annexon by 18.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company's stock valued at $12,693,000 after purchasing an additional 331,269 shares during the last quarter.

Remove Ads

Annexon Stock Performance

Shares of ANNX traded up $0.15 during trading hours on Wednesday, reaching $1.96. The stock had a trading volume of 3,124,591 shares, compared to its average volume of 1,775,623. Annexon, Inc. has a 12 month low of $1.73 and a 12 month high of $7.85. The stock has a market capitalization of $215.03 million, a PE ratio of -1.87 and a beta of 1.14. The company's 50-day moving average is $2.91 and its two-hundred day moving average is $4.88.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on ANNX shares. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, December 17th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Annexon in a report on Tuesday, March 4th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.